fda approves semaglutide for cardiovascular risk reduction First Treatment to Reduce of Serious Heart Problems Specifically in Adults with Obesity Wegovy® receives FDA approval for

doi: 10.1109/TPAMI.2023.3299568 56 Alvarez-MonMAGmezAMOrozcoALaheraGSosaMDDiazDet al

As explained by Stanford, People might begin with oral medications to achieve initial weight loss or glycemic control, and then transition to injections if more intensive treatment is needed. On the flip side, a step-down approach can be used to simplify things or lower treatment intensity after reaching goals

The usual dose is 50 mg per kg (22.7 mg per pound) of body weight a day injected into a vein

[3] Laboratory tests typically measure total B12 rather than the active form (holotranscobalamin), which can sometimes lead to misleading results

Telehealth can be especially helpful for those starting retatrutide or adjusting doses, providing timely guidance without the need for in-person appointments

Additionally, baseline metabolic health, insulin sensitivity, stomach motility, and concurrent medications affect efficacy and tolerability